profiles Archives

Health By Isabella Cueto

‘We don’t have a say’: Siobhan Wescott wants to elevate the voices of Native Americans in public health

Health By Usha Lee McFarling

She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group

Heavyweights By Isabella Cueto

Denizens of ‘The Cave’ became changemakers and leaders. Here are some of its notable alumni

A portrait of Joshua Miele at his home in Berkeley, Calif.

Heavyweights By Isabella Cueto

‘Where the bats hung out’: How a basement hideaway at UC Berkeley nurtured a generation of blind innovators

Exclusive By Erin Brodwin

In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’

Health By Andrew Joseph

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

Health Tech By Casey Ross

Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money

Heavyweights By Lev Facher

Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science

Heavyweights By Nicholas Florko

A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust

Heavyweights By Usha Lee McFarling

A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19

Heavyweights By Eric Boodman

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

In the Lab By Alex Hogan, Hyacinth Empinado and Crystal Milner

Watch: How did you get your start in science? And other questions with the STAT Wunderkinds

Heavyweights By Shraddha Chakradhar

At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science

Health By Natalya Ortolano

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Exclusive By Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

Health By Andrew Joseph

‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response

Health By Andrew Joseph

After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?

Politics By STAT Staff

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

Health Tech By Megan Thielking

A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation

Biotech By Nicholas Florko

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

Heavyweights By Lev Facher

How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda

Biotech By Nicholas Florko

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

Pharma By Eric Boodman

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

Politics By Nicholas Florko

BIO’s new board chair on the industry’s bad reputation: ‘That’s ridiculous’

Politics By Lev Facher and Nicholas Florko

Most Read

The internet’s funniest doctor is in on the joke

Inside the downfall of longevity crusader Aubrey de Grey — and the cult of personality that concealed a pattern of harassment

How Ashish Jha became network TV’s everyman expert on Covid

Inequality ‘surrounds you’: A Black doctor returns to hard-hit Louisiana after treating and contracting Covid-19 in New York

With science and scripture, a Baltimore pastor is fighting Covid-19 vaccine skepticism

‘I really don’t know what happened to Jim’: Friends ask where James Watson’s odious attitudes about race came from

An outsider claimed to make genome-editing history — and the world snapped to attention

Out of prison, the ‘father of gene therapy’ faces a harsh reality: a tarnished legacy and an ankle monitor

All Coverage

‘We don’t have a say’: Siobhan Wescott wants to elevate the voices of Native Americans in public health

She was told ‘girls don’t do that.’ Now Margaret-Mary Wilson is a top executive at UnitedHealth Group

Denizens of ‘The Cave’ became changemakers and leaders. Here are some of its notable alumni

‘Where the bats hung out’: How a basement hideaway at UC Berkeley nurtured a generation of blind innovators

In a new role at health tech startup Maven, Neel Shah wants to make sure pregnant people aren’t ‘lost’

Q&A: The CEO of the Alzheimer’s Association on the approval of Aduhelm — and why critics should stop dwelling on the decision

Verily’s new big hire, Amy Abernethy, on her plans to transform clinical trials — and bring in money

Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science

A former FDA chief, brimming with experience but lacking in niceties, surprises Washington by winning Biden’s trust

A ‘duty to warn’: An ER doctor, shaped by war and hardship, chronicles the searing realities of Covid-19

As a kid, his factory work paid for his dad’s cancer care. As an oncologist, his research offers more than survival

Watch: How did you get your start in science? And other questions with the STAT Wunderkinds

At the top of her field, a Covid-19 researcher fights back against a different kind of virus: sexism and power imbalances in science

‘We do belong here’: The scientist behind #BlackInNeuro hopes to transform a Twitter movement into a lasting community

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

‘We didn’t follow through’: He wrote the Ebola ‘lessons learned’ report for Obama. Now he weighs in on coronavirus response

After 40 years, the Alzheimer’s Association sees signs of progress against a devastating disease. Is it real?

Sen. Chuck Grassley takes your questions on drug prices, insulin, and innovation

A Q&A with FDA’s Amy Abernethy on how the agency is grappling with digital health regulation

The Alzheimer’s Drug Discovery Foundation still expects new treatment options approved by 2025

How Joe Grogan, a former pharma lobbyist, upended Trump’s drug pricing agenda

The company behind the first-ever CBD-based drug is now eyeing everything from multiple sclerosis to autism

First it was aspirin, then Xarelto. What’s Bayer’s next big thing?

BIO’s new board chair on the industry’s bad reputation: ‘That’s ridiculous’

Frontrunner to lead FDA, dogged by controversies, has developed knack for confronting them

Subscribe to STAT for $15 per month lorem ipsum